Evidence map›Paper›PMID 25875833›Full record

ArticlePloS one2015

Immunomodulator-based enhancement of anti smallpox immune responses.

Osmarie Martínez, Eric Miranda, Maite Ramírez, Saritza Santos, Carlos Rivera, Luis Vázquez, Tomás Sánchez, Raymond L Tremblay, Eddy Ríos-Olivares, Miguel Otero

Open access · goldAbstract read
In one paragraph

Article in PloS one, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers.

0numbers the graph read from it
0cells of the map it votes in
10citing papers in PubMed
0.7field-weighted citation impact, top 30% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

10 citing papers in PubMed, 11 citations in OpenAlex.

  1. Article
  2. Adjuvant effect of dendritic cells activator Imiquimod in genetic immunization with HIV-1 p55 Gag.Journal of immunological techniques in infectious diseases · 2023
    Article
  3. Article
  4. Review
  5. Article
  6. Article
  7. Article
  8. Article
  9. Defending against smallpox: a focus on vaccines.Expert review of vaccines · 2016
    Review
  10. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 4 institutions in 1 country.

Osmarie MartínezDepartment of Microbiology, University of Puerto Rico, Medical Sciences Campus, San Juan, Puerto Rico.
Eric MirandaDepartment of Microbiology, University of Puerto Rico, Medical Sciences Campus, San Juan, Puerto Rico; Department of Microbiology Universidad Central del Caribe School of Medicine, Bayamón, Puerto Rico.
Maite RamírezDepartment of Microbiology, University of Puerto Rico, Medical Sciences Campus, San Juan, Puerto Rico.
Saritza SantosDepartment of Microbiology, University of Puerto Rico, Medical Sciences Campus, San Juan, Puerto Rico.
Carlos RiveraDepartment Biology, University of Puerto Rico, Rio Piedras Campus, San Juan, Puerto Rico.
Luis VázquezDepartment Biology, University of Puerto Rico, Rio Piedras Campus, San Juan, Puerto Rico.
Tomás SánchezDepartment Biology, University of Puerto Rico, Rio Piedras Campus, San Juan, Puerto Rico.
Raymond L TremblayDepartment of Biology, University of Puerto Rico, Humacao, Puerto Rico; Department of Biology, University of Puerto Rico, Rio Piedras Campus, San Juan, Puerto Rico; Center for Applied Tropical Ecology and Conservation, University of Puerto Rico, Rio Piedras campus, San Juan, Puerto Rico.
Eddy Ríos-OlivaresDepartment of Microbiology Universidad Central del Caribe School of Medicine, Bayamón, Puerto Rico.
Miguel OteroDepartment of Microbiology, University of Puerto Rico, Medical Sciences Campus, San Juan, Puerto Rico.
University of Puerto Rico, Medical Sciences Campus · PRUniversity of Puerto Rico at Río Piedras · PRCentral University of the Caribbean · PRUniversity of Puerto Rico at Humacao · PR

Funding

SCIENCE AND TECHNOLOGY COMPETENCY & EDUCATION CORE (STCE)P20GM103475 · NIGMS · UNIVERSITY OF PUERTO RICO MED SCIENCES · PI Humberto Guillermo Ortiz-Zuazaga · 2012 to 2026
$52.9M
SUPPLEMENT FOR RENOVATION OF ANIMAL FACILITIES AT INSTITUTE OF NEUROBIOLOGYG12RR003051 · NCRR · UNIVERSITY OF PUERTO RICO MED SCIENCES · PI RODRIGUEZ-MEDINA, JOSE R · 1986 to 2011
$28.1M
UNIVERSITY MEDICAL RESEARCH CENTERG12RR003035 · NCRR · UNIVERSIDAD CENTRAL DEL CARIBE · PI CUBANO, LUIS ANGEL · 1986 to 2011
$26.7M
RISE Option III: MBRS RISE at the UPR Medical Sciences CampusR25GM061838 · NIGMS · UNIVERSITY OF PUERTO RICO MED SCIENCES · PI CADILLA, CARMEN LYDIA · 2000 to 2021
$25.5M
TRANSLATIONAL PROTEOMICS CENTERG12MD007600 · NIMHD · UNIVERSITY OF PUERTO RICO MED SCIENCES · PI FERNANDEZ-REPOLLET, EMMA · 2012 to 2016
$11.0M
UNIVERSIDAD CENTRAL DEL CARIBE BIOMEDICAL RESEARCH CENTERSG12MD007583 · NIMHD · UNIVERSIDAD CENTRAL DEL CARIBE · PI RODRIGUEZ, JOSE GINEL · 2012 to 2016
$8.4M
NCRR NIH HHS G12 RR003035NCRR NIH HHS G12 RR003051NIGMS NIH HHS P20 GM103475NIGMS NIH HHS R25 GM061838NIMHD NIH HHS G12 MD007583NIMHD NIH HHS G12 MD007600
6 · The paper itself

Abstract

backgroundThe current live vaccinia virus vaccine used in the prevention of smallpox is contraindicated for millions of immune-compromised individuals. Although vaccination with the current smallpox vaccine produces protective immunity, it might result in mild to serious health complications for some vaccinees. Thus, there is a critical need for the production of a safe virus-free vaccine against smallpox that is available to everyone. For that reason, we investigated the impact of imiquimod and resiquimod (Toll-like receptors agonists), and the codon-usage optimization of the vaccinia virus A27L gene in the enhancement of the immune response, with intent of producing a safe, virus-free DNA vaccine coding for the A27 vaccinia virus protein.

methodsWe analyzed the cellular-immune response by measuring the IFN-γ production of splenocytes by ELISPOT, the humoral-immune responses measuring total IgG and IgG2a/IgG1 ratios by ELISA, and the TH1 and TH2 cytokine profiles by ELISA, in mice immunized with our vaccine formulation.

resultsThe proposed vaccine formulation enhanced the A27L vaccine-mediated production of IFN-γ on mouse spleens, and increased the humoral immunity with a TH1-biased response. Also, our vaccine induced a TH1 cytokine milieu, which is important against viral infections.

conclusionThese results support the efforts to find a new mechanism to enhance an immune response against smallpox, through the implementation of a safe, virus-free DNA vaccination platform.

Indexed as

Adjuvants, ImmunologicAnimalsAntibodies, ViralAntigens, ViralCytokinesDisease Models, AnimalEnzyme-Linked Immunospot AssayEpitope MappingFemaleImmunity, CellularImmunity, HumoralImmunoglobulin IsotypesImmunologic FactorsMiceSmallpoxSmallpox VaccineAdjuvants, ImmunologicAntibodies, ViralAntigens, ViralCytokinesImmunoglobulin IsotypesImmunologic FactorsSmallpox VaccineVaccines, Synthetic

Identifiers

PMID25875833
PMCPMC4395221
OpenAlexW2067241734

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.